NewCardio Competitors

NewCardio (OTCMKTS:NWCI) and Medtronic (NYSE:MDT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Institutional and Insider Ownership

79.2% of Medtronic shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

NewCardio has a beta of 4.43, meaning that its share price is 343% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for NewCardio and Medtronic, as provided by MarketBeat.com.

Medtronic has a consensus price target of $124.2692, suggesting a potential upside of 0.30%. Given Medtronic's higher possible upside, analysts plainly believe Medtronic is more favorable than NewCardio.

Profitability

This table compares NewCardio and Medtronic's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares NewCardio and Medtronic's revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than NewCardio.

Summary

Medtronic beats NewCardio on 9 of the 10 factors compared between the two stocks.

NewCardio (OTCMKTS:NWCI) and Sonova (OTCMKTS:SONVY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Profitability

This table compares NewCardio and Sonova's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and target prices for NewCardio and Sonova, as provided by MarketBeat.com.

Volatility and Risk

NewCardio has a beta of 4.43, indicating that its stock price is 343% more volatile than the S&P 500. Comparatively, Sonova has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Earnings & Valuation

This table compares NewCardio and Sonova's gross revenue, earnings per share and valuation.

Sonova has higher revenue and earnings than NewCardio.

Institutional and Insider Ownership

1.1% of Sonova shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Sonova beats NewCardio on 3 of the 4 factors compared between the two stocks.

Varian Medical Systems (NYSE:VAR) and NewCardio (OTCMKTS:NWCI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.

Profitability

This table compares Varian Medical Systems and NewCardio's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Varian Medical Systems and NewCardio's gross revenue, earnings per share and valuation.

Varian Medical Systems has higher revenue and earnings than NewCardio.

Risk and Volatility

Varian Medical Systems has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, NewCardio has a beta of 4.43, meaning that its share price is 343% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Varian Medical Systems and NewCardio, as reported by MarketBeat.

Varian Medical Systems presently has a consensus price target of $159.3571, indicating a potential downside of 10.00%. Given Varian Medical Systems' higher possible upside, equities analysts plainly believe Varian Medical Systems is more favorable than NewCardio.

Institutional & Insider Ownership

87.0% of Varian Medical Systems shares are held by institutional investors. 0.8% of Varian Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Varian Medical Systems beats NewCardio on 7 of the 8 factors compared between the two stocks.

NewCardio (OTCMKTS:NWCI) and Masimo (NASDAQ:MASI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Profitability

This table compares NewCardio and Masimo's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares NewCardio and Masimo's revenue, earnings per share and valuation.

Masimo has higher revenue and earnings than NewCardio.

Institutional & Insider Ownership

81.6% of Masimo shares are owned by institutional investors. 11.5% of Masimo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

NewCardio has a beta of 4.43, indicating that its share price is 343% more volatile than the S&P 500. Comparatively, Masimo has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for NewCardio and Masimo, as provided by MarketBeat.

Masimo has a consensus target price of $272.20, indicating a potential upside of 13.63%. Given Masimo's higher probable upside, analysts plainly believe Masimo is more favorable than NewCardio.

Summary

Masimo beats NewCardio on 8 of the 9 factors compared between the two stocks.

NewCardio (OTCMKTS:NWCI) and Getinge (OTCMKTS:GNGBY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for NewCardio and Getinge, as provided by MarketBeat.

Profitability

This table compares NewCardio and Getinge's net margins, return on equity and return on assets.

Risk & Volatility

NewCardio has a beta of 4.43, indicating that its share price is 343% more volatile than the S&P 500. Comparatively, Getinge has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Valuation & Earnings

This table compares NewCardio and Getinge's top-line revenue, earnings per share and valuation.

Getinge has higher revenue and earnings than NewCardio.

Insider & Institutional Ownership

0.0% of Getinge shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Getinge beats NewCardio on 6 of the 7 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and NewCardio (OTCMKTS:NWCI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Valuation and Earnings

This table compares LivaNova and NewCardio's gross revenue, earnings per share (EPS) and valuation.

NewCardio has lower revenue, but higher earnings than LivaNova.

Profitability

This table compares LivaNova and NewCardio's net margins, return on equity and return on assets.

Insider and Institutional Ownership

89.1% of LivaNova shares are held by institutional investors. 0.5% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

LivaNova has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, NewCardio has a beta of 4.43, indicating that its stock price is 343% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for LivaNova and NewCardio, as provided by MarketBeat.com.

LivaNova currently has a consensus target price of $69.3333, indicating a potential downside of 14.79%. Given LivaNova's higher possible upside, equities research analysts clearly believe LivaNova is more favorable than NewCardio.

Summary

LivaNova beats NewCardio on 7 of the 9 factors compared between the two stocks.